Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis

31 January 2022: Meta-Analysis

Xiulan Peng ^1AE* , Wei Zeng ^2BF* , Bing Tang ^3CF* , Anbing He ^1B , Min Zhang ^1B , Renfeng Luo ^4AB*

DOI: 10.12659/MSM.933449

Med Sci Monit 2022; 28:e933449

Table 2 Subgroup analyses of pooled HRs and 95% CIs for OS based on different factors.

Subgroup analysis	No. of studies	No. of patients	Effects model	HR (95% CI)	P value	Heterogeneity
Subgroup analysis	No. of studies	No. of patients	Effects model	HR (95% CI)	P value	I2 (%)	p value
OS
NOS score
>7	9	2190	Random	1.36 (1.08–1.72)	0.010	70.8	0.001
≤7	7	963	Fixed	1.46 (1.29–1.65)		16.1	0.303
Sample size
≥168	8	2453	Fixed	1.53 (1.37–1.70)		15.5	0.308
	8	700	Random	1.37 (1.05–1.80)	0.020	64.1	0.007
Treatment
Chemotherapy	10	2090	Random	1.34 (1.11–1.62)	0.002	63.7	0.003
Mixed	6	1063	Fixed	1.62 (1.39–1.89)		0.0	0.646
Cut-off value
≥161	9	1836	Fixed	1.37 (1.22–1.53)		37.3	0.120
	7	1317	Random	1.41 (1.11–1.80)	0.005	68.6	0.004
Cut-off method
ROC curve	8	1687	Fixed	1.48 (1.29–1.71)		41.7	0.100
Median	4	787	Random	1.22 (0.88–1.70)	0.238	78.0	0.003
NA	3	375	Fixed	1.62 (1.34–1.95)		0.0	0.774
X-title	1	304	–	1.59 (1.02–2.48)	0.041	–	–
Ethnicity
Caucasian	3	369	Random	1.30 (0.71–2.39)	0.394	87.8
Asian	13	2784	Fixed	1.43 (1.30–1.58)		25.1	0.190
Total	16	3153	Random	1.43 (1.25–1.64)		54.1	0.005
CI – confidence interval; HR – hazard ratio; OS – overall survival; DFS – disease-free survival; ROC – receiver operating characteristics curve; PLR – platelet to lymphocyte ratio (I >50% or